F2G Ltd receives european orphan drug designation for its lead candidate F901318
F2G Ltd, a UK Biotech developing novel therapies for life threatening fungal infections, has announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted orphan drug status to its lead clinical candidate, F901318, for the treatment of invasive Aspergillosis and rare mould infections caused by Scedosporium species.